ACADIA Pharmaceuticals Inc. - Common Stock (ACAD)
Frequently Asked Questions About ACADIA Pharmaceuticals Inc. - Common Stock (ACAD)
How does ACADIA Pharmaceuticals prioritize patient outcomes?
ACADIA Pharmaceuticals prioritizes patient outcomes by centering its research and development efforts on understanding the needs and experiences of patients with neurological and psychiatric diseases. Through clinical trials and real-world data, the company aims to ensure that its therapies adequately address symptoms and improve overall well-being.
How has ACADIA Pharmaceuticals performed financially?
ACADIA Pharmaceuticals' financial performance is often reported in its quarterly and annual earnings reports. The company's revenue primarily comes from sales of Nuplazid, and its financial outlook is influenced by ongoing clinical development efforts, market penetration, and overall demand for its products.
How is ACADIA Pharmaceuticals positioned in the competitive landscape?
ACADIA Pharmaceuticals is positioned as a significant player in the biopharmaceutical industry, particularly within the neuropsychiatry segment. The company's unique focus on specific disorders, strong clinical data, and established product like Nuplazid contribute to its competitive differentiation in the market.
Is ACADIA Pharmaceuticals a publicly traded company?
Yes, ACADIA Pharmaceuticals Inc. is a publicly traded company, listed on the Nasdaq stock exchange under the ticker symbol ACAD. This allows investors to buy and sell shares of the company, reflecting its financial performance and market value.
What are the primary products of ACADIA Pharmaceuticals Inc.?
ACADIA Pharmaceuticals is best known for its lead product, Nuplazid (pimavanserin), which is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company is also exploring additional indications and product candidates in its pipeline aimed at addressing unmet medical needs in neuropsychiatry.
What challenges does ACADIA Pharmaceuticals face?
Like many biopharmaceutical companies, ACADIA Pharmaceuticals faces several challenges, including regulatory hurdles, competition from other drug developers, the need for successful clinical trial outcomes, and the pressure to maintain sustainable revenue growth while managing development costs.
What clinical trials has ACADIA Pharmaceuticals conducted?
ACADIA Pharmaceuticals has conducted multiple clinical trials, primarily focused on the safety and efficacy of its lead product, Nuplazid, as well as other compounds in its pipeline. These trials have included Phase 1, 2, and 3 studies, evaluating various indications, dosing regimens, and treatment outcomes.
What does ACADIA Pharmaceuticals Inc. do?
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for neurological and psychiatric diseases. The company is particularly known for its research and development efforts in treating conditions such as Parkinson's disease, schizophrenia, and other movement disorders.
What is Nuplazid and how does it work?
Nuplazid (pimavanserin) is an antipsychotic medication developed by ACADIA Pharmaceuticals specifically for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It works by selectively targeting serotonin receptors in the brain, thereby providing an effective treatment without worsening motor symptoms associated with Parkinson's disease.
What is the company's approach to corporate social responsibility?
ACADIA Pharmaceuticals demonstrates its commitment to corporate social responsibility through various initiatives aimed at community engagement, patient advocacy, and ethical business practices. The company actively supports educational programs and partnerships that promote awareness of neurological and psychiatric disorders.
What is the company's pipeline for drug development?
ACADIA Pharmaceuticals has an active pipeline that includes several investigational drugs targeting a variety of neurological and psychiatric conditions. The pipeline expands beyond Nuplazid, aiming to explore potential treatments that address additional patient needs in neuropsychiatry.
What is the purpose of ACADIA's research and development activities?
The purpose of ACADIA's research and development activities is to create innovative therapies that can effectively treat challenging neurological and psychiatric conditions. The company aims to address significant unmet medical needs by developing drugs that can improve patients' quality of life and reduce the burden of these disorders.
What is the vision and mission of ACADIA Pharmaceuticals?
The vision and mission of ACADIA Pharmaceuticals revolve around improving the lives of individuals with neurological and psychiatric disorders. The company strives to deliver innovative and effective treatment options while advancing scientific knowledge in these critical areas of healthcare.
What partnerships or collaborations does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has established various partnerships and collaborations with academic institutions and pharmaceutical companies to advance its drug development pipeline. These collaborations often focus on research initiatives that support the development of innovative therapies for neuropsychiatric disorders.
What recent developments or news has ACADIA Pharmaceuticals announced?
Recent developments at ACADIA Pharmaceuticals often include updates on clinical trial results, new product launches, strategic partnerships, or financial announcements. Staying abreast of these developments via press releases and news articles is crucial for investors and stakeholders interested in the company.
What therapeutic areas does ACADIA Pharmaceuticals focus on?
ACADIA Pharmaceuticals focuses primarily on neurological and psychiatric disorders. Its research pipeline includes drugs for conditions such as schizophrenia, Parkinson's disease psychosis, and other related diseases, indicating the company's commitment to improving the lives of patients with these challenging disorders.
When was ACADIA Pharmaceuticals Inc. founded?
ACADIA Pharmaceuticals Inc. was founded in 1993. Since its inception, the company has dedicated itself to the discovery and development of drugs designed to treat neurodegenerative and psychiatric disorders, making a significant impact in these fields.
Where is ACADIA Pharmaceuticals Inc. headquartered?
ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California. This location allows the company to be part of a vibrant biotech ecosystem, facilitating collaboration and innovation in the pharmaceutical industry.
Who leads ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals is led by an experienced management team with extensive backgrounds in the biopharmaceutical industry. The leadership includes professionals with expertise in drug development, regulatory affairs, marketing, and finance, guiding the company's strategic direction and operational execution.
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 15.41
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 2.51B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 162.63M shares outstanding.